{"abstract":"The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled \"General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products.\" This draft guidance recommends studies, including comparative in vitro studies, which should be conducted to demonstrate that a proposed generic solid oral opioid drug product is no less abuse-deterrent than its reference listed drug.","action":"Notice of availability.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/03/25/2016-06766.html","cfr_references":[],"citation":"81 FR 16186","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by May 24, 2016.","disposition_notes":null,"docket_ids":["Docket No. FDA-2016-D-0785"],"dockets":[],"document_number":"2016-06766","effective_on":null,"end_page":16187,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/03/25/2016-06766.xml","html_url":"https://www.federalregister.gov/documents/2016/03/25/2016-06766/general-principles-for-evaluating-the-abuse-deterrence-of-generic-solid-oral-opioid-drugs-products","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-06766?publication_date=2016-03-25","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-03-25/2016-06766/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":1783,"last_updated":"2026-11-22 14:15:04 -0500"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-03-25/pdf/2016-06766.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-06766.pdf?1458823578","publication_date":"2016-03-25","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/03/25/2016-06766.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2016-D-0785","supporting_documents_count":0,"docket_id":"FDA-2016-D-0785","regulation_id_number":null,"title":"General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drugs Products","checked_regulationsdotgov_at":"2016-05-25T05:01:11Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":16186,"subtype":null,"title":"General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drugs Products; Draft Guidance for Industry; Availability","toc_doc":"General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drugs Products","toc_subject":"Draft Guidance for Industry:","topics":[],"type":"Notice","volume":81}